Overview

Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo

Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs. Placebo in Adults with Atopic Dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
DermBiont, Inc.
Treatments:
Anti-Bacterial Agents
Anti-Infective Agents